文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

炔雌醇硫酸盐无需液体复苏经雌激素受体快速保护重度失血心血管系统

Ethinyl estradiol sulfate acts without fluid resuscitation through estrogen receptors to rapidly protect the cardiovascular system from severe hemorrhage.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论大鼠创伤-失血模型显示,炔雌醇硫酸盐无需液体复苏即可在30分钟内经雌激素受体快速改善心血管功能并减轻凋亡与炎症。

该研究在大鼠创伤-失血模型(中线开腹+控制性失血60%血容量、不做液体复苏)中,于失血后30分钟给予炔雌醇硫酸盐(EES),观察其对心血管功能的影响及机制。结果显示EES与雌激素受体结合的IC50为1.52×10⁻⁸ Mol/L,可显著升高平均动脉压和dP/dT(但未完全恢复),并大幅降低凋亡、NF-κB活化及诱导型一氧化氮合酶产生的NO,同时使磷酸化eNOS恢复至生理水平。上述信号恢复早于心肌收缩力恢复,且可被雌激素受体拮抗剂阻断。作者认为EES作用为非基因组效应,速度契合“黄金一小时”干预窗口。

要点

  • 在大鼠创伤-失血(60%失血、无液体复苏)模型中,失血后30分钟给予EES可显著升高平均动脉压和dP/dT,但未完全恢复至正常。
  • EES与大鼠雌激素受体结合的IC50为1.52×10⁻⁸ Mol/L,符合药理效力范围。
  • EES大幅降低凋亡水平、NF-κB活化及诱导型一氧化氮合酶产生的NO,并使磷酸化eNOS恢复至生理水平。
  • EES的心血管保护作用依赖雌激素受体结合,可被雌激素受体拮抗剂阻断。
  • 细胞信号恢复早于心肌收缩力恢复,30分钟采样窗口提示为非基因组效应,可能限于细胞表面受体结合。

适用人群与场景

  • 大鼠创伤-失血模型:中线开腹+控制性失血60%血容量,不做液体复苏。
  • 原文未提及人体适用人群、纳入或排除标准。

诊断标准与关键阈值

  • 大鼠雌激素受体结合IC50为1.52×10⁻⁸ Mol/L。
  • 失血后30分钟为采样与观察窗口。

处置流程与药物剂量

  • 失血后30分钟给予炔雌醇硫酸盐(EES),原文未提及具体剂量、给药途径与频次。
  • 原文未提及液体复苏方案(模型设计为不做液体复苏)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:大鼠创伤-失血模型基础研究;样本量原文未提及。
  • EES与雌激素受体结合IC50为1.52×10⁻⁸ Mol/L。
  • 失血后30分钟内EES显著升高平均动脉压和dP/dT,但未完全恢复。
  • EES大幅降低凋亡水平、NF-κB活化及诱导型一氧化氮合酶产生的NO,磷酸化eNOS恢复至生理水平。
  • 雌激素受体拮抗剂可阻断EES作用;信号恢复早于心肌收缩力恢复。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠创伤-失血模型)。
  • 局限:原文未述局限性。

对床旁实践的改变

  • 原文提示EES无需液体复苏即可在30分钟内经雌激素受体快速改善心血管功能,速度契合“黄金一小时”干预窗口。
  • 上述结果来自大鼠模型,原文未提及人体应用证据。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Our in vivo rodent and pig model evidenced that estrogen and its derivative, ethinyl estradiol sulfate (EES), promote survival following hemorrhagic shock. To determine its mechanism, we first confirmed EES binding to estrogen receptor (ER) and improving/restoring cellular signaling, countering the assumption that EES, an ethinyl estradiol metabolite, is inactive. In addition, we examined if EES acts rapidly, consistent with nongenomic signaling. We selected the biomarkers of cardiovascular performance, reduction of apoptosis and proinflammatory responses, and elaboration of nitric oxide (NO) to validate efficacy.

METHODS: A rat trauma-hemorrhage model, consisting of a midline laparotomy and controlled bleeding (60% blood loss) without fluid resuscitation, was used. At 30 minutes after hemorrhage, heart performance was monitored, and Western blots were used to quantify biochemical analytes. The specificity of EES for ER was profiled with ER antagonists. Binding studies by Sekisui XenoTech (Kansas City, KS) determined an LD50 value for EES binding the rat ER.

RESULTS: The EES IC50 value was 1.52 × 10-8 Mol/L, consistent with pharmacologic efficacy. Ethinyl estradiol sulfate raised mean arterial pressure and ±derivative of pressure over time (dP/dT) significantly (but did not fully restore) within a 30-minute window. Levels of apoptosis and activation of NF-κB were dramatically reduced, as was elaboration of nitric oxide (NO) by inducible nitric oxide synthase. Phospho-endothelial nitric oxide synthase (eNOS) was restored to physiological levels. The restoration of cellular signaling occurs before restoration of cardiac contractility.

CONCLUSION: Ethinyl estradiol sulfate is a potent drug for improving heart performance, which also dramatically reduces damage by apoptosis, proinflammatory activity, and NO production, validating that EES can blunt multiple harmful outcomes arising from hypoxia and hypovolemia. The actions are dependent on receptor engagement, where specificity is confirmed by ER antagonists. The constraint of a 30-minute sampling window affirms that the responses are nongenomic and very likely restricted to cell-surface receptor engagement. The rapidity of these responses makes EES promising for intervention in the "golden hour."

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Hubbard WJ, Yang S, Chaudry IH, et al. Ethinyl estradiol sulfate acts without fluid resuscitation through estrogen receptors to rapidly protect the cardiovascular system from severe hemorrhage. J Trauma Acute Care Surg. 2021. PMID: 33048911. doi:10.1097/TA.0000000000002978

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。